MRS Measurement of Glutamate and GABA Metabolism in Brain

This study is currently recruiting participants.
Verified August 2013 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00109174
First received: April 22, 2005
Last updated: March 14, 2014
Last verified: August 2013
  Purpose

This study will use magnetic resonance spectroscopy (MRS) to measure in the brain the transfer of [13]C as it is naturally metabolized from glucose to specific chemical transmitters. From this method, we can measure the rate of production of an important excitatory neurotransmitter (glutamate) as well as an inhibitory neurotransmitter (GABA)....


Condition Intervention
Healthy
Procedure: Magnetic Resonance Spectroscopy

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: MRS (Magnetic Resonance Spectroscopy) Measurement of Glutamate and GABA Metabolism in Brain

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 120
Study Start Date: April 2005
Intervention Details:
    Procedure: Magnetic Resonance Spectroscopy
    N/A
Detailed Description:

(13)C is a stable (i.e., non-radioactive) isotope of carbon with a natural abundance of approximately 1%. Following infusion of [(13)C]glucose and/or [(13)C]acetate, in vivo MRS (magnetic resonance spectroscopy) can monitor the rate of flux of the (13)C atom from glucose and/or acetate to glutamate to glutamine. Thus, this procedure can provide measure of glutamate (GLU) and glutamine (GLN) turnover in brain. We have established parameters to obtain these measurements in nonhuman primate brain. The current protocol seeks approval to optimize MRS parameters for human brain using the GE 3T, and the Siemens 7T device.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

Age: 18-65 years

Diagnosis: Healthy

EXCLUSION CRITERIA:

Abnormal fasting blood glucose level (normal values are 70-115 mg/dL); All subjects must have a fasting blood glucose level of within the normal values of 70-115 mg/dL

Serious medical illness (including diabetes) as determined from H& P or laboratory testing; All subjects must meet none of the Axis I diagnoses

Prescription psychotropic medication; drug free period must be greater than 3 weeks for anticholinergics and benzodiazepine and greater than 8 weeks for fluoxetine, antipsychotics, anticonvulsants

Claustrophobia

Pregnancy; All women with child-bearing potential will have a blood and/or urine pregnancy test within 24 hours prior to the MRS study to exclude pregnancy

Any condition that increases risk for MRI (e.g., pacemaker, metallic foreign body in the eye, etc.)

Unable to lay on one's back for MRI/MRS scans

Positive HIV test

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00109174

Contacts
Contact: Maria D Ferraris Araneta, C.R.N.P. (301) 496-9423 ferrarism@mail.nih.gov
Contact: Robert B Innis, M.D. (301) 594-1368 robert.innis@nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010    prpl@mail.cc.nih.gov   
Sponsors and Collaborators
Investigators
Principal Investigator: Robert B Innis, M.D. National Institute of Mental Health (NIMH)
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00109174     History of Changes
Other Study ID Numbers: 050144, 05-M-0144
Study First Received: April 22, 2005
Last Updated: March 14, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Glutamate
Excitatory Amino Acid
Neurochemistry
GABA
Magnetic Resonance Spectroscopy

ClinicalTrials.gov processed this record on April 17, 2014